A disturbing number of corporate M&A transactions end up being disappointing wastes of time and shareholders' money. In fact, I would go so far as to say that a lot of deals are about executive ego, hiding an inability to grow organically, or simply giving institutional shareholders the illusion that management is "active".

I am putting all of that aside today. I actually do think that the combination of Allscripts (Nasdaq:MDRX) and Eclipsys (Nasdaq:ECLP) is one that makes a lot of sense. Accordingly, this may be one of the relatively rare deals that actually benefits all parties involved.

Tutorial: The Basics Of Mergers and Acquisitions

The Players
Allscripts is already one of the larger players in healthcare IT, with an impressive array of electronic healthcare record management, e-prescribing and practice management software packages. All told, Allscripts has about 160,000 physicians as clients, as well as about 800 hospitals and 8,000 post-acute facilities (like nursing homes and hospices)

Eclipsys is slightly different. First, Eclipsys is more concentrated than Allscripts, as nearly 40% of its revenue comes from about 20 customers and a single hospital customer accounts for more than 10% of its revenue base. Still, the company has good penetration in top hospitals, and boasts enterprise solutions that serve both the clinical and business needs of customers in the hospital market. (For more, see A Checklist For Successful Medical Technology Investment.)

The Combination
This deal will see Allscripts buying Eclipsys in a $1.3 billion stock deal where Eclipsys shareholders get 1.2 Allscripts shares and a roughly 19% premium. Once combined, the two companies will boast a client base of about 180,000 physicians, 1,500 hospitals and more than 10,000 post-acute sites.

Not only does this deal provide scale, but it looks like there should be real synergies. Eclipsys adds a big acute care business, and that is an area where Allscripts was relatively weak. All said, there does not appear to be a large amount of overlap so it should allow customers to benefit from "best of breed" across the combined platform. That said, there will be an integration process and that could create delays in new product introductions and other transition issues that could temporarily expose the company to its competitors. (For more, see What Makes An M&A Deal Work?)

The Landscape
Healthcare IT has been an attractive market for quite some time, but seems to have plenty of room to run, as some estimates indicate market penetration in the area of 10%. As you might imagine, there is no shortage of players in the space.

Cerner (Nasdaq:CERN) is already a major player in the space, and one that is transitioning from its historical focus on hospitals to physician practices. Not only does Cerner boast a sizable foreign business, but its software-as-service offerings reduce the upfront costs to customers (likely an attractive feature for physician practices).

There are additional major players with their eyes on this market. General Electric (NYSE:GE), Siemens (NYSE:SI) and Oracle (Nasdaq:ORCL) all have some measure of interest in the space and sizable marketing assets to wield. On the smaller side of the market, Athenahealth (Nasdaq:ATHN) has posted strong growth so far with its web-based revenue management products and is trying to build its business in medical records.

Bottom Line
With this announced acquisition, Allscripts' majority shareholder Misys (a British software company) will be reducing its stake from 55% down to about 10% . That could put a ceiling on the shares and represents a risk to the deal. This is because if Misys is stymied in its plans, it could impair Allscripts' deal. What's more, there are the above-mentioned competitors waiting to exploit the inevitable turbulence that will result when the two companies combine forces. Despite all this, this is still a deal that makes sense and one where I think both shareholder groups can benefit in the coming years.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Term

    What are Non-GAAP Earnings?

    Non-GAAP earnings are a company’s earnings that are not reported according to Generally Accepted Accounting Principles.
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares FTSE RAFI US 1000

    Find out about the PowerShares FTSE RAFI U.S. 1000 ETF, and explore detailed analysis of the fund that invests in undervalued stocks.
  3. Options & Futures

    Use Options to Hedge Against Iron Ore Downslide

    Using iron ore options is a way to take advantage of a current downslide in iron ore prices, whether for producers or traders.
  4. Stock Analysis

    Fortinet: A Great Play on Cybersecurity

    Discover how a healthy product mix, large-business deal growth and the boom of the cybersecurity industry are all driving Fortinet profits.
  5. Stock Analysis

    2 Catalysts Driving Intrexon to All-Time Highs

    Examine some of the main reasons for Intrexon stock tripling in price between 2014 and 2015, and consider the company's future prospects.
  6. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  7. Charts & Patterns

    Understand How Square Works before the IPO

    Square is reported to have filed for an IPO. For interested investors wondering how the company makes money, Investopedia takes a look at its business.
  8. Technical Indicators

    4 Ways to Find a Penny Stock Worth Millions

    Thinking of trading in risky penny stocks? Use this checklist to find bargains, not scams.
  9. Professionals

    Chinese Slowdown Affects Iron Ore Market

    The Chinese economy's ongoing slowdown is having a major impact on iron ore demand.
  10. Investing Basics

    Why do Debt to Equity Ratios Vary From Industry to Industry?

    Obtain a better understanding of the debt/equity ratio, and learn why this fundamental financial metric varies significantly between industries.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Profit Margin

    A category of ratios measuring profitability calculated as net ...
  3. Quarter - Q1, Q2, Q3, Q4

    A three-month period on a financial calendar that acts as a basis ...
  4. Debt Ratio

    A financial ratio that measures the extent of a company’s or ...
  5. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing ...
  6. Net Present Value - NPV

    The difference between the present values of cash inflows and ...
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  3. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  4. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  5. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  6. What is the difference between the return on total assets and an interest rate?

    Return on total assets (ROTA) represents one of the profitability metrics. It is calculated by taking a company's earnings ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!